The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Lessons Learnt from Assembling Screening Libraries for Drug Discovery for Neglected Diseases
Open accessAbstract
To enable the establishment of a drug discovery operation for neglected diseases, out of 2.3 million commercially available compounds 222 552 compounds were selected for an in silico library, 57 438 for a diverse general screening library, and 1 697 compounds for a focused kinase set. Compiling these libraries required a robust strategy for compound selection. Rules for unwanted groups were defined and selection criteria to enrich for lead‐like compounds which facilitate straightforward structure–activity relationship exploration were established. Further, a literature and patent review was undertaken to extract key recognition elements of kinase inhibitors (“core fragments”) to assemble a focused library for hit discovery for kinases. Computational and experimental characterisation of the general screening library revealed that the selected compounds 1) span a broad range of lead‐like space, 2) show a high degree of structural integrity and purity, and 3) demonstrate appropriate solubility for the purposes of biochemical screening. The implications of this study for compound selection, especially in an academic environment with limited resources, are considered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Drugs for bad bugs: confronting the challenges of antibacterial discovery
Payne, D. J., Gwynn, M. N., Holmes, D. J., & Pompliano, D. L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2201 · Cited by 2,512
Protein kinases — the major drug targets of the twenty-first century?
Cohen, P. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd773 · Cited by 2,186
A ‘Rule of Three’ for fragment-based lead discovery?
Congreve, M., Carr, R., Murray, C., & Jhoti, H. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02831-9 · Cited by 1,354
A decade of fragment-based drug design: strategic advances and lessons learned
Hajduk, P. J., & Greer, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2220 · Cited by 1,064
Hit and lead generation: beyond high-throughput screening
Bleicher, K. H., Böhm, H.-J., Müller, K., & Alanine, A. I. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1086 · Cited by 1,056
Integration of virtual and high-throughput screening
Bajorath, J. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd941 · Cited by 930
Drug development for neglected diseases: a deficient market and a public-health policy failure
Trouiller, P., Olliaro, P., Torreele, E., Orbinski, J., Laing, R., & Ford, N. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09096-7 · Cited by 893
Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery
Hann, M. M., Leach, A. R., & Harper, G. (2001) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci000403i · Cited by 877
The Design of Leadlike Combinatorial Libraries
Teague, S. J., Davis, A. M., Leeson, P. D., & Oprea, T. (1999) · Angewandte Chemie International Edition · doi:10.1002/(sici)1521-3773(19991216)38:24<3743::aid-anie3743>3.0.co;2-u · Cited by 870
Is There a Difference between Leads and Drugs? A Historical Perspective
Oprea, T. I., Davis, A. M., Teague, S. J., & Leeson, P. D. (2001) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci010366a · Cited by 769
Virtual ligand screening: strategies, perspectives and limitations
Klebe, G. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.05.012 · Cited by 664
Property distribution of drug-related chemical databases*
Oprea, T. I. (2000) · Journal of Computer-Aided Molecular Design · doi:10.1023/a:1008130001697 · Cited by 628
Opportunities and Challenges in Antiparasitic Drug Discovery
Pink, R., Hudson, A., Mouriès, M.-A., & Bendig, M. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1824 · Cited by 545
Innovative lead discovery strategies for tropical diseases
Nwaka, S., & Hudson, A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2144 · Cited by 521
Pursuing the leadlikeness concept in pharmaceutical research
Hann, M. M., & Oprea, T. I. (2004) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2004.04.003 · Cited by 515
Liao, J. J.-L. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm0608107 · Cited by 507
Molecular similarity analysis in virtual screening: foundations, limitations and novel approaches
Eckert, H., & Bajorath, J. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.01.011 · Cited by 466
Designing screens: how to make your hits a hit
Walters, W. P., & Namchuk, M. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1063 · Cited by 374
Virtual Exploration of the Small‐Molecule Chemical Universe below 160 Daltons
Fink, T., Bruggesser, H., & Reymond, J. (2005) · Angewandte Chemie International Edition · doi:10.1002/anie.200462457 · Cited by 353
Drug discovery and development for neglected parasitic diseases
Renslo, A. R., & McKerrow, J. H. (2006) · Nature Chemical Biology · doi:10.1038/nchembio837 · Cited by 337
Protein kinases as drug targets in trypanosomes and Leishmania
Naula, C., Parsons, M., & Mottram, J. C. (2005) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2005.08.018 · Cited by 228
Strategic Pooling of Compounds for High-Throughput Screening
Hann, M., Hudson, B., Lewell, X., Lifely, R., Miller, L., & Ramsden, N. (1999) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci990423o · Cited by 225
A journey of hope: lessons learned from studies on rare diseases and orphan drugs
WÄSTFELT, M., FADEEL, B., & HENTER, J. ‐. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01666.x · Cited by 184
Balakin, K., Savchuk, N., & Tetko, I. (2006) · Current Medicinal Chemistry · doi:10.2174/092986706775197917 · Cited by 183
Lahana, R. (1999) · Drug Discovery Today · doi:10.1016/s1359-6446(99)01393-8 · Cited by 160
Two decades of orphan product development
Haffner, M. E., Whitley, J., & Moses, M. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd919 · Cited by 137
Baurin, N., Baker, R., Richardson, C., Chen, I., Foloppe, N., Potter, A., Jordan, A. M., Roughley, S. D., Parratt, M. J., Greaney, P., et al. (2004) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci034260m · Cited by 118
Relationships between Molecular Complexity, Biological Activity, and Structural Diversity
Schuffenhauer, A., Brown, N., Selzer, P. M., Ertl, P., & Jacoby, E. (2005) · Journal of Chemical Information and Modeling · doi:10.1021/ci0503558 · Cited by 102
An Empirical Process for the Design of High-Throughput Screening Deck Filters
Pearce, B. C., Sofia, M. J., Good, A. C., Drexler, D. M., & Stock, D. A. (2006) · Journal of Chemical Information and Modeling · doi:10.1021/ci050504m · Cited by 97
A New Approach to Finding Natural Chemical Structure Classes
Xu, J. C. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm010520k · Cited by 89
Holloway, G. A., Baell, J. B., Fairlamb, A. H., Novello, P. M., Parisot, J. P., Richardson, J., Watson, K. G., & Street, I. P. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.11.090 · Cited by 52
Makara, G. M. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm0700316 · Cited by 31
A Novel Approach to Combinatorial Library Design
Nilakantan, R. (2002) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207024607310 · Cited by 27
“In-House Likeness”: Comparison of Large Compound Collections Using Artificial Neural Networks
Mureşan, S., & Sadowski, J. (2005) · Journal of Chemical Information and Modeling · doi:10.1021/ci049702o · Cited by 17
A fresh look at pharmaceutical screening library design
Nilakantan, R., & Nunn, D. S. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02793-4 · Cited by 17
Herrling, P. L. (2007) · Nature · doi:10.1038/449174a · Cited by 7
The art and practice of structure-based drug design: A molecular modeling perspective
(1996) · doi:10.1002/(sici)1098-1128(199601)16:1<3::aid-med1>3.0.co;2-6
Cited by
Daina, A., Michielin, O., & Zoete, V. (2017) · Scientific Reports · doi:10.1038/srep42717 · Cited by 18,367
Gaulton, A., Hersey, A., Nowotka, M., Bento, A. P., Chambers, J., Mendez, D., Mutowo, P., Atkinson, F., Bellis, L. J., Cibrián-Uhalte, E., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1074 · Cited by 2,330
Discovery of a structural class of antibiotics with explainable deep learning
Wong, F., Zheng, E. J., Valeri, J. A., Donghia, N. M., Anahtar, M. N., Omori, S., Li, A., Cubillos-Ruiz, A., Krishnan, A., Jin, W., et al. (2024) · Nature · doi:10.1038/s41586-023-06887-8 · Cited by 458
A novel multiple-stage antimalarial agent that inhibits protein synthesis
Baragaña, B., Hallyburton, I., Lee, M. C. S., Norcross, N. R., Grimaldi, R., Otto, T. D., Proto, W. R., Blagborough, A. M., Meister, S., Wirjanata, G., et al. (2015) · Nature · doi:10.1038/nature14451 · Cited by 454
Self-citationConstrained Bayesian optimization for automatic chemical design using variational autoencoders
Griffiths, R.-R., & Hernández-Lobato, J. M. (2020) · Chemical Science · doi:10.1039/c9sc04026a · Cited by 339
Metadata
- Authors
- Brenk, R., Schipani, A., James, D., Krasowski, A., Gilbert, I. H., Frearson, J., & Wyatt, P. G.
- Venue
- ChemMedChem
- Publisher
- Wiley
- Published
- 2008-03-07
- Volume
- 3
- Issue
- 3
- Pages
- 435-444
- ISSN
- 1860-7179 (ISSN-L)
- 1860-7187
- OpenAlex
- W2113364934
- Cited by
- 709
- References
- 40
- FWCI
- 7.23
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
